ProCE Banner Activity

GMALL 08/2013: First Results From the Risk-Adapted, MRD-Stratified Trial in Adults With Newly Diagnosed ALL/LBL

Slideset Download
Conference Coverage
Preliminary results were promising in a large, population-based, risk-adapted trial using a pediatric-based regimen in patients aged 18-55 years with newly diagnosed ALL/LBL.

Released: December 20, 2021

Expiration: December 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation